Inhibition of IL-10 production by maternal antibodies against group b streptococcus GAPDH confers immunity to offspring by favoring neutrophil recruitment

PLoS Pathogens

Volumn 7, Issue 11, 2011, Pages

  Madureira, Pedro ^a,b   Andrade, Elva Bonifácio ^a,b   Gama, Bernardo ^a   Oliveira, Liliana ^a,b   Moreira, Susana ^c   Ribeiro, Adília ^a,b   Correia Neves, Margarida ^c,d   Trieu Cuot, Patrick ^e   Vilanova, Manuel ^a,b   Ferreira, Paula ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 10; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CARBON SOURCE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME STRUCTURE; FEMALE; GLUCOSE BLOOD LEVEL; GROUP B STREPTOCOCCAL INFECTION; IMMUNOTHERAPY; MOUSE; NEUTROPHIL; NEUTROPHIL RECRUITMENT; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OPSONIZATION; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PROGENY; STREPTOCOCCUS AGALACTIAE; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; IMMUNOLOGY; NEUTROPHIL CHEMOTAXIS; PATHOGENICITY; STREPTOCOCCUS INFECTION; VACCINATION;

BACTERIA (MICROORGANISMS); MUS; STREPTOCOCCUS SP. 'GROUP B';

ANIMALS; ANIMALS, NEWBORN; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION, PASSIVE; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 81755177757     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002363     Document Type: Article

References (76)

1. Baker CJ, Barrett FF, Gordon RC, Yow MD, (1973) Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr 82: 724-729.
2. Barton LL, Feigin RD, Lins R, (1973) Group B beta hemolytic streptococcal meningitis in infants. J Pediatr 82: 719-723.
3. Edwards MS, (2006) Issues of antimicrobial resistance in group B streptococcus in the era of intrapartum antibiotic prophylaxis. Semin Pediatr Infect Dis 17: 149-152.
4. Heath PT, Schuchat A, (2007) Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol 21: 411-424.
5. Johri AK, Paoletti LC, Glaser P, Dua M, Sharma PK, et al. (2006) Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 4: 932-942.
6. Zangwill KM, Schuchat A, Wenger JD, (1992) Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ 41: 25-32.
7. Jordan HT, Farley MM, Craig A, Mohle-Boetani J, Harrison LH, et al. (2008) Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 27: 1057-1064.
8. Fluegge K, Siedler A, Heinrich B, Schulte-Moenting J, Moennig MJ, et al. (2006) Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 117: e1139-1145.
9. Hajdu A, Blystad H, Hoiby EA, Klouman E, Schimmer B, et al. (2006) Unexpected increase in case fatality of invasive group B streptococcal infections in infants in Norway, January-July 2006. Euro Surveill 11: E060727 060722.
10. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, et al. (2004) Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363: 292-294.
11. Baltimore RS, (2007) Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin Perinatol 31: 33-38.
12. Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, et al. (2008) Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008 727505.
13. Doran KS, Nizet V, (2004) Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy. Mol Microbiol 54: 23-31.
14. Amundson NR, Flores AE, Hillier SL, Baker CJ, Ferrieri P, (2005) DNA macrorestriction analysis of nontypeable group B streptococcal isolates: clonal evolution of nontypeable and type V isolates. J Clin Microbiol 43: 572-576.
15. Kong F, Lambertsen LM, Slotved HC, Ko D, Wang H, et al. (2008) Use of phenotypic and molecular serotype identification methods to characterize previously nonserotypeable group B streptococci. J Clin Microbiol 46: 2745-2750.
16. Ramaswamy SV, Ferrieri P, Flores AE, Paoletti LC, (2006) Molecular characterization of nontypeable group B streptococcus. J Clin Microbiol 44: 2398-2403.
17. Ramaswamy SV, Ferrieri P, Madoff LC, Flores AE, Kumar N, et al. (2006) Identification of novel cps locus polymorphisms in nontypable group B Streptococcus. J Med Microbiol 55: 775-783.
18. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, et al. (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309: 148-150.
19. Margarit I, Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, et al. (2009) Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 199: 108-115.
20. Friedman CA, Robbins KK, Temple DM, Miller CJ, Rawson JE, (1996) Survival and neutrophil kinetics in infants with severe group B streptococcal disease treated with gamma globulin. J Perinatol 16: 439-442.
21. Hill HR, Bohnsack JF, Morris EZ, Augustine NH, Parker CJ, et al. (1988) Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol 141: 3551-3556.
22. Hemming VG, McCloskey DW, Hill HR, (1976) Pneumonia in the neonate associated with group B streptococcal septicemia. Am J Dis Child 130: 1231-1233.
23. Quirante J, Ceballos R, Cassady G, (1974) Group B beta-hemolytic streptococcal infection in the newborn. I. Early onset infection. Am J Dis Child 128: 659-665.
24. Anderson DC, Hughes BJ, Smith CW, (1981) Abnormal mobility of neonatal polymorphonuclear leukocytes. Relationship to impaired redistribution of surface adhesion sites by chemotactic factor or colchicine. J Clin Invest 68: 863-874.
25. Buhrer C, Graulich J, Stibenz D, Dudenhausen JW, Obladen M, (1994) L-selectin is down-regulated in umbilical cord blood granulocytes and monocytes of newborn infants with acute bacterial infection. Pediatr Res 36: 799-804.
26. Koenig JM, Yoder MC, (2004) Neonatal neutrophils: the good, the bad, and the ugly. Clin Perinatol 31: 39-51.
27. Cancelier AC, Petronilho F, Reinke A, Constantino L, Machado R, et al. (2009) Inflammatory and oxidative parameters in cord blood as diagnostic of early-onset neonatal sepsis: a case-control study. Pediatr Crit Care Med 10: 467-471.
28. Romagnoli C, Frezza S, Cingolani A, De Luca A, Puopolo M, et al. (2001) Plasma levels of interleukin-6 and interleukin-10 in preterm neonates evaluated for sepsis. Eur J Pediatr 160: 345-350.
29. Madureira P, Baptista M, Vieira M, Magalhaes V, Camelo A, et al. (2007) Streptococcus agalactiae GAPDH is a virulence-associated immunomodulatory protein. J Immunol 178: 1379-1387.
30. Jones N, Bohnsack JF, Takahashi S, Oliver KA, Chan MS, et al. (2003) Multilocus sequence typing system for group B streptococcus. J Clin Microbiol 41: 2530-2536.
31. Lamy MC, Dramsi S, Billoet A, Reglier-Poupet H, Tazi A, et al. (2006) Rapid detection of the "highly virulent" group B Streptococcus ST-17 clone. Microbes Infect 8: 1714-1722.
32. Poyart C, Reglier-Poupet H, Tazi A, Billoet A, Dmytruk N, et al. (2008) Invasive group B streptococcal infections in infants, France. Emerg Infect Dis 14: 1647-1649.
33. Seifert KN, McArthur WP, Bleiweis AS, Brady LJ, (2003) Characterization of group B streptococcal glyceraldehyde-3-phosphate dehydrogenase: surface localization, enzymatic activity, and protein-protein interactions. Can J Microbiol 49: 350-356.
34. Cornacchione P, Scaringi L, Fettucciari K, Rosati E, Sabatini R, et al. (1998) Group B streptococci persist inside macrophages. Immunology 93: 86-95.
35. Monteiro GC, Hirata R Jr, Andrade AF, Mattos-Guaraldi AL, Nagao PE, (2004) Surface carbohydrates as recognition determinants in non-opsonic interactions and intracellular viability of group B Streptococcus strains in murine macrophages. Int J Mol Med 13: 175-180.
36. Quach D, van Sorge NM, Kristian SA, Bryan JD, Shelver DW, et al. (2009) The CiaR response regulator in group B Streptococcus promotes intracellular survival and resistance to innate immune defenses. J Bacteriol 191: 2023-2032.
37. Valenti-Weigand P, Benkel P, Rohde M, Chhatwal GS, (1996) Entry and intracellular survival of group B streptococci in J774 macrophages. Infect Immun 64: 2467-2473.
38. Liu GY, Nizet V, (2004) Extracellular virulence factors of group B Streptococci. Front Biosci 9: 1794-1802.
39. Marshall-Clarke S, Reen D, Tasker L, Hassan J, (2000) Neonatal immunity: how well has it grown up? Immunol Today 21: 35-41.
40. Lemke H, Coutinho A, Lange H, (2004) Lamarckian inheritance by somatically acquired maternal IgG phenotypes. Trends Immunol 25: 180-186.
41. Belderbos ME, van Bleek GM, Levy O, Blanken MO, Houben ML, et al. (2009) Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin Immunol 133: 228-237.
42. Chelvarajan L, Popa D, Liu Y, Getchell TV, Stromberg AJ, et al. (2007) Molecular mechanisms underlying anti-inflammatory phenotype of neonatal splenic macrophages. J Leukoc Biol 82: 403-416.
43. Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, et al. (2009) Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 183: 7150-7160.
44. Sun CM, Deriaud E, Leclerc C, Lo-Man R, (2005) Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 22: 467-477.
45. Genovese F, Mancuso G, Cuzzola M, Biondo C, Beninati C, et al. (1999) Role of IL-10 in a neonatal mouse listeriosis model. J Immunol 163: 2777-2782.
46. Rainsford E, Reen DJ, (2002) Interleukin 10, produced in abundance by human newborn T cells, may be the regulator of increased tolerance associated with cord blood stem cell transplantation. Br J Haematol 116: 702-709.
47. Cusumano V, Genovese F, Mancuso G, Carbone M, Fera MT, et al. (1996) Interleukin-10 protects neonatal mice from lethal group B streptococcal infection. Infect Immun 64: 2850-2852.
48. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A, (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822.
49. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al. (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444-3451.
50. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A, (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
51. Saraiva M, O'Garra A, (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170-181.
52. Berkman N, John M, Roesems G, Jose PJ, Barnes PJ, et al. (1995) Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. J Immunol 155: 4412-4418.
53. Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, et al. (1999) Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 163: 1537-1544.
54. Marfaing-Koka A, Maravic M, Humbert M, Galanaud P, Emilie D, (1996) Contrasting effects of IL-4, IL-10 and corticosteroids on RANTES production by human monocytes. Int Immunol 8: 1587-1594.
55. Zuany-Amorim C, Creminon C, Nevers MC, Nahori MA, Vargaftig BB, et al. (1996) Modulation by IL-10 of antigen-induced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity. J Immunol 157: 377-384.
56. Zuany-Amorim C, Haile S, Leduc D, Dumarey C, Huerre M, et al. (1995) Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest 95: 2644-2651.
57. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
58. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP, (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31: 2848-2856.
59. Reed SG, Brownell CE, Russo DM, Silva JS, Grabstein KH, et al. (1994) IL-10 mediates susceptibility to Trypanosoma cruzi infection. J Immunol 153: 3135-3140.
60. Roque S, Nobrega C, Appelberg R, Correia-Neves M, (2007) IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy. J Immunol 178: 8028-8035.
61. Silva RA, Appelberg R, (2001) Blocking the receptor for interleukin 10 protects mice from lethal listeriosis. Antimicrob Agents Chemother 45: 1312-1314.
62. Cleat PH, Wells C, Coid CR, (1984) Electron microscopic evidence of antibody entry into neutrophils after phagocytosis of highly virulent group B streptococci. J Gen Microbiol 130: 3059-3061.
63. Schuit KE, DeBiasio R, (1980) Kinetics of phagocyte response to group B streptococcal infections in newborn rats. Infect Immun 28: 319-324.
64. Levy O, Martin S, Eichenwald E, Ganz T, Valore E, et al. (1999) Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 104: 1327-1333.
65. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S, (1995) High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 171: 229-232.
66. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A, (1995) High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 63: 2109-2112.
67. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, et al. (2000) Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 342: 15-20.
68. Schuchat A, (1998) Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 11: 497-513.
69. Abu-Asab MS, Laassri M, Amri H, (2010) Algorithmic assessment of vaccine-induced selective pressure and its implications on future vaccine candidates. Adv Bioinformatics 2010 178069.
70. Haas R, Meyer TF, (1986) The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion. Cell 44: 107-115.
71. Helm RA, Seifert HS, (2009) Pilin antigenic variation occurs independently of the RecBCD pathway in Neisseria gonorrhoeae. J Bacteriol 191: 5613-5621.
72. Hill SA, Davies JK, (2009) Pilin gene variation in Neisseria gonorrhoeae: reassessing the old paradigms. FEMS Microbiol Rev 33: 521-530.
73. Kline KA, Criss AK, Wallace A, Seifert HS, (2007) Transposon mutagenesis identifies sites upstream of the Neisseria gonorrhoeae pilE gene that modulate pilin antigenic variation. J Bacteriol 189: 3462-3470.
74. Tushinski RJ, Oliver IT, Guilbert LJ, Tynan PW, Warner JR, et al. (1982) Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 28: 71-81.
75. He RQ, Yang MD, Zheng X, Zhou JX, (1995) Isolation and some properties of glycated D-glyceraldehyde-3-phosphate dehydrogenase from rabbit muscle. Biochem J 309 (Pt 1): 133-139.
76. Mountassif D, Baibai T, Fourrat L, Moutaouakkil A, Iddar A, et al. (2009) Immunoaffinity purification and characterization of glyceraldehyde-3-phosphate dehydrogenase from human erythrocytes. Acta Biochim Biophys Sin (Shanghai) 41: 399-406.